Sell2Wales.gov.wales uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies.

Accept cookies Cookie Settings

View Notice

The buyer is not using this website to administer the notice. To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Add notice to my Sell2Wales Interest List

Notice Details

Title: Community Lipid Management Service
Published by: NHS BLMK Clinical Commissioning Group
Publication Date: 25/11/2021
Deadline Date:
Deadline Time:
Notice Type: Contract Award Notice
Has Documents: No
Has ESPD: No
Abstract:

NHS BLMK CCG secured Pathway Transformation Funding (PTF) to support the adoption of a new lipid management pathway and the establishment of community lipid services. The Community Lipid service will offer:

• A full assessment of people referred with CVD and/or FH and also uncontrolled hypercholesterolaemia or mixed dyslipidemia, including review of current and previous lipid lowering treatments, adherence with treatment regimes and any reasons for discontinuation.

• Pharmacological management and monitoring of effectiveness and tolerability in line with pathways agreed with the commissioner.

• Requesting of appropriate pathology tests at appropriate intervals through the relevant pathology system.

• Electronic prescription of relevant medications, in sufficient quantity to meet the requirements for uptitration between review contacts.

• Comprehensive documentation of each clinical contact in the shared clinical record on SystmOne.

• Support for self-management and education on the significance of managing cardiovascular risk factors, including cholesterol.

• Appropriate signposting to other services to support optimisation of health and wellbeing, including weight management, smoking cessation, alcohol support and talking therapies.

• Onward referral to specialist lipid services of patients with uncontrolled lipids despite maximum tolerated oral therapy, in line with criteria and pathways agreed with the commissioner.

• Clinical assessment of people with clinical features suggestive of suspected FH (as defined by the commissioner), with onward referral as appropriate to specialist lipid services.

• Clear treatment plans with appropriate patient-driven uptitration of therapy, timing of repeat lipid testing and scheduling of follow-up to allow maximal impact from each clinical contact.

Contract award notice

Results of the procurement procedure

Directive 2014/24/EU - Public Sector Directive

Directive 2014/24/EU

Section I: Contracting entity

I.1) Name and addresses

NHS BLMK Clinical Commissioning Group

Capability House

Silsoe, Bedfordshire

MK45 4HR

UK

Contact person: Samuel Naxton

E-mail: samuel.naxton@attain.co.uk

NUTS: UKH24

Internet address(es)

Main address: https://www.blmkccg.nhs.uk/

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Community Lipid Management Service

Reference number: ACE-0490-2021-BLMK

II.1.2) Main CPV code

85100000

 

II.1.3) Type of contract

Services

II.1.4) Short description

NHS BLMK Clinical Commissioning Group has awarded a contract to Evexia Health Ltd following an 'Open' procurement process to deliver a new Community Lipid Management Service.

The purpose of the Community Lipid Service is to provide a consistent, evidence-based approach to lipid management across BLMK CCG. The Community Lipid Clinic will form part of a new pathway developed with key stakeholders across BLMK, in line with evidenced-based best practice. The service will be funded to provide clinical activity to optimise lipid management in populations at very high risk of CVD (as defined by the commissioner) and provide clinical assessment for familial hypercholesterolemia in people meeting appropriate clinical criteria (as defined by the commissioner), in line with locally developed evidence-based pathways. The Community Lipid Clinic will accept referrals of people meeting the relevant clinical criteria who are registered with a GP practice in Bedfordshire, Luton and Milton Keynes Integrated Care System.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement

Value excluding VAT: 200 000.00  GBP

II.2) Description

II.2.3) Place of performance

NUTS code:

UKH24


Main site or place of performance:

Bedfordshire, Luton and Milton Keynes

II.2.4) Description of the procurement

NHS BLMK CCG secured Pathway Transformation Funding (PTF) to support the adoption of a new lipid management pathway and the establishment of community lipid services. The Community Lipid service will offer:

• A full assessment of people referred with CVD and/or FH and also uncontrolled hypercholesterolaemia or mixed dyslipidemia, including review of current and previous lipid lowering treatments, adherence with treatment regimes and any reasons for discontinuation.

• Pharmacological management and monitoring of effectiveness and tolerability in line with pathways agreed with the commissioner.

• Requesting of appropriate pathology tests at appropriate intervals through the relevant pathology system.

• Electronic prescription of relevant medications, in sufficient quantity to meet the requirements for uptitration between review contacts.

• Comprehensive documentation of each clinical contact in the shared clinical record on SystmOne.

• Support for self-management and education on the significance of managing cardiovascular risk factors, including cholesterol.

• Appropriate signposting to other services to support optimisation of health and wellbeing, including weight management, smoking cessation, alcohol support and talking therapies.

• Onward referral to specialist lipid services of patients with uncontrolled lipids despite maximum tolerated oral therapy, in line with criteria and pathways agreed with the commissioner.

• Clinical assessment of people with clinical features suggestive of suspected FH (as defined by the commissioner), with onward referral as appropriate to specialist lipid services.

• Clear treatment plans with appropriate patient-driven uptitration of therapy, timing of repeat lipid testing and scheduling of follow-up to allow maximal impact from each clinical contact.

II.2.5) Award criteria

Quality criterion: Quality / Weighting: 100%

Price / Weighting:  0%

II.2.11) Information about options

Options: Yes

Description of options:

Contract duration is for 12 months (01st January 2022 to 31st December 2022) with an option to extend for a further 12 months subject to funding, learning and benefits outcomes.

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number in the OJ S:

2021/S 000-018335

Section V: Award of contract

Contract No: M1J4AY Community Lipid Service 2021-22

Title: Community Lipid Service

A contract/lot is awarded: Yes

V.2 Award of contract

V.2.1) Date of conclusion of the contract

27/10/2021

V.2.2) Information about tenders

Number of tenders received: 2

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Evexia Health Ltd

2a Malzeard Road

Luton

LU3 1BD

UK

NUTS: UKH21

The contractor is an SME: No

V.2.4) Information on value of the contract/lot (excluding VAT)

Total value of the contract/lot: : 200 000.00  GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information

Contract Duration:

12 months with an option to extend for a further 12 months subject to funding, learning and benefits outcomes.

Contract Value:

£100,000 per annum

Total contract value for a 24 month period:

£200,000

VI.4) Procedures for review

VI.4.1) Review body

High Court of Justice of England and Wales

Strand

London

WC2A 2LL

UK

VI.5) Date of dispatch of this notice

24/11/2021


Information added to the notice since publication.

Additional information added to the notice since it's publication.
No further information has been uploaded.
Main Contact: samuel.naxton@attain.co.uk
Admin Contact: N/a
Technical Contact: N/a
Other Contact: N/a

Commodity Categories

Commodity Categories
IDTitleParent Category
85100000Health servicesHealth and social work services

Delivery Locations

Delivery Locations
IDDescription
100UK - All

Alert Region Restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

Alert Region Restrictions
There are no alert restrictions for this notice.

Copyright © Sell2Wales